In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

STADA Arzneimittel AG

https://www.stada.com/

Latest From STADA Arzneimittel AG

EMA OKs First Drug To Prevent RSV Infection In Babies

A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.

Europe Approvals

Stada And Xbrane Win EU Endorsement For Ranibizumab

Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.

Biosimilars Approvals

Stada Leads Competition To Zytiga In Europe

Stada has launched abiraterone film-coated tablets, a generic version of Janssen’s Zytiga, in 21 markets across Europe as protection for the branded treatment for metastatic prostate cancer expired.

Launches Generic Drugs

Stada Enjoys Robust First Half For Generics And Biosimilars

With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.

Sales & Earnings Strategy
See All

Company Information

UsernamePublicRestriction

Register